

Location(s):	<input type="checkbox"/> ALL	<input type="checkbox"/> FH	<input type="checkbox"/> GP <input type="checkbox"/> RO <input type="checkbox"/> Troy	<input type="checkbox"/> Dearborn <input type="checkbox"/> Taylor <input type="checkbox"/> Trenton <input type="checkbox"/> Wayne	<input checked="" type="checkbox"/> AMB BMG/SA6	<input checked="" type="checkbox"/> AMB Independent	<input type="checkbox"/> Other
Module:	<input checked="" type="checkbox"/> EpicCare AMB <input type="checkbox"/> ANC: _____ <input type="checkbox"/> ANES <input type="checkbox"/> ASAP <input type="checkbox"/> Beacon <input type="checkbox"/> Cupid <input type="checkbox"/> Device Integration <input type="checkbox"/> EpicCare Inpatient <input type="checkbox"/> Haiku/Canto <input type="checkbox"/> Lab <input type="checkbox"/> MISD <input type="checkbox"/> myChart <input type="checkbox"/> OpTime <input type="checkbox"/> Radiant <input type="checkbox"/> RevCycle <input type="checkbox"/> Stork-OB <input type="checkbox"/> Willow (Rx)						
Training Required:	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No						
Category:	<input checked="" type="checkbox"/> CMS <input type="checkbox"/> Core Measures <input type="checkbox"/> MU <input type="checkbox"/> PCMH <input type="checkbox"/> PQRS						
Target Audience:	Ambulatory Providers						
Subject:	Michigan Automated Prescription System (MAPS) Review						
Effective Date:	May 21, 2018						

Prescribers can access condensed MAPS functions from the Charting Navigator using the links on the right of the screen. This provides links to 1) MAPS and the 2) Opioid Start Talking form.

Testpatient, Alice
Female, 118y.o., 01/01/1900
Admitted: Yes
PCP, Care Team: Test, Inpatient Physician, MD, ...

MRN: 9003... Ht: None Allergies: **Unknown:...** Advance Directive F... Outside Inf... Research: None
 CSN: 1003... Wt: None **Health Maintenance** MyChart: Pending Coverage:... Registries: Wellness R...
 Test, Inpati... Last BMI: N... **BestPractice Advisor...** Pharmacy: None Location/Status: G 11
 Off-Site Visi... Phone: M:6... **Daily MME: 45 mg...**

5/10/2018 visit with Test, Inpatient Physician, MD for Off-Site Visit

BestPractice Visit Diagnoses Problem List Informational Notice MAPS Meds & Orders SmartSets

MAPS Review

MAPS
Click to view MAPS.

Opioid Start Talking Form

Medications & Orders

Search for new order + New Order + Patient-Reported

Name Dose, Route, Frequency ✓ ⚙

Outpatient and Clinic-Administered Medications

lisinopril (PRINIVIL, ZESTRIL) 5 MG PO Tab 5 mg, Oral, DAILY ✓ ⚙ ✕ ⌵

oxycodONE (ROXICODONE) 5 MG/5ML PO Solution 5 mg, Oral, EVERY 4 HOURS AS NEEDED ✓ ⚙ ✕ ⌵

✓ Mark All Taking ✓ Mark as Reviewed Never Reviewed

Click here to select a pharmacy

Associate Providers

SmartSets

Search for new SmartSet + Add

Beaumont Health - oneChart DEV - TROY FAMILY MED CTR - BH CLIN SRVCS OE PHYSICIAN

Male, 42y.o., 12/1... PCP... MRN: 9... Ht... Last BM... Allergies: Gadoli... BestPra... MyChart: Active Outside... Research: None Loc...
Admitted: No CSN: 1... Wt... Phone... Health Mainten... Pharmacy: CA... Covera... Registries: Diab...

Chart Review

Snapshot Enc Notes Lab Micro/Path Img Anc Reports Cardiology ECG

Family Medicine Current Meds Getting to Know Me MAPS MAPS

MAPS Review

Add or Remove Buttons from Toolbar

2	My Story	Getting to Know Me
3	MAPS	MAPS
4		

Per State Law, the MAPS report must be reviewed when writing a controlled substance prescription with a duration greater than three (3) days.

Click to view MAPS.

Use the following links to access the "Opioid Start Talking" Form and other useful Opioid Legislation information.

Add Current Remove Accept Cancel

BH CLIN SRVCS OE PHY... 1294 Result Notes Results Chart Completion Patient Calls All Reminders 1:44 AM

The **MAPS** report button will automatically default to the Chart Review/Snapshot toolbar.

If you previously personalized your toolbar buttons and want the **MAPS** button to display on your workspace, use the **wrench** and **up** arrow to reposition the buttons.

***Note: If an error occurs when accessing MAPS from Chart Review, open an encounter and try again.

MAPS Review Navigator contains 5 Hyperlinks:

- 1) Click to View MAPS will launch you directly into the State website
- 2) Opioid Start Talking Form
- 3) NARx Score Explanation
- 4) Controlled Substance Legislation Summary
- 5) Michigan Health and Human Services Opioid Site

Beaumont Health - oneChart DEV - TROY FAMILY MED CTR - INPATIENT PHYSICIAN TEST

Female, 118y.o., 01... PCP... MRN: 90... Ht... Last BMI... Allergies: Unknown... BestPract... MyChart: Pending Daily... Outside I... Research: None Loc...
Admitted: Yes CSN: 10... Wt... Phone: M... Health Maintenance Pharmacy: None Coverag... Registries: Wellne...

Chart Review

Snapshot Enc Notes Lab Micro/Path Img Anc Reports Cardiology ECG Meds LDAs

Family Medicine My Story MAPS MAPS

MAPS Review

Per State Law, the MAPS report must be reviewed when writing a controlled substance prescription with a duration greater than three (3) days.

Click to view MAPS.

Use the following links to access the "Opioid Start Talking" Form and other useful Opioid Legislation information.

Opioid Start Talking Form Controlled Substance Legislation Summary

NARx Scores Explanation Michigan Health and Human Services' Opioids Site

NARx Scores

Admission (Discharged) from 4/4/2018 in 6 ST GYN TEAM CARE A	
Narcotic Score	261
Sedative Score	110
Stimulant Score	000

INPATIENT PHYSICIAN TE... 91 Chart Completion My Incomplete Notes My Open Charts My Open Encounters Cosign Notes 6:28 PM

NARxCare Report

Tutorials: Overview | Narx Scores | Overdose Risk Score | Lorazepam Milligram Equivalents

ALICE TESTPATIENT, 118F

Narx Report Resources

Date: 5/10/2018

+ TESTPATIENT, ALICE

- Risk Indicators

NARX SCORES			OVERDOSE RISK SCORE	ADDITIONAL RISK INDICATORS
Narcotic	Sedative	Stimulant	140 (Range 000-999)	
261	110	000		

Explanation and Guidance

This NarxCare report is based on search criteria supplied and the data entered by the dispensing pharmacy. For more information about any prescription, please contact the pharmacy or the prescriber. NarxCare scores and reports are intended to aid, not replace, medical decision making. None of the information presented should be used for justification for providing or refusing to provide medications. The information on this report is not warranted as accurate or complete.

Graphs

RX GRAPH

Narcotic Sedative Stimulant

1. Click to
View MAPS

(Completed form will be scanned into the EHR.)

2. Opioid Start
Talking Form

Chart Review

Synopsis Snapshot Enc Notes

Family Medicine

MAPS Review

Per State Law, the MAPS report is required for all patients receiving a controlled substance.

MAPS

[Click to view MAPS.](#)

Use the following links to:

[Opioid Start Talking Form](#)

[NARx Scores Explanation](#)

NARx Scores

Narcotic Score
Sedative Score
Stimulant Score

OPIOID START TALKING
(MUST BE INCLUDED IN THE PATIENT'S MEDICAL RECORD)
Michigan Department of Health and Human Services

Patient Name _____ Date of Birth _____

Name of Controlled Substance containing an Opioid _____

Dosage _____ Quantity Prescribed (For a minor, if signature is not the parent or guardian, the prescriber must limit the opioid to a single, 72 hour supply) _____

Number of refills _____

A controlled substance is a drug or other substance that the United States Drug Enforcement Administration has identified as having a potential for abuse. My provider shared the following:

- The risks of substance use disorder and overdose associated with the controlled substance containing an opioid.
- Individuals with mental illness and substance use disorders may have an increased risk of addiction to a controlled substance. (Required only for minors.)
- Mixing opioids with benzodiazepines, alcohol, muscle relaxers, or any other drug that may depress the central nervous system can cause serious health risks, including death or disability. (Required only for minors.)
- For a female who is pregnant or is of reproductive age, the heightened risk of short and long-term effects of opioids, including but not limited to neonatal abstinence syndrome.
- Any other information necessary for patients to use the drug safely and effectively as found in the patient counseling information section of the labeling for the controlled substance.

000

NARxCare Report

*Per CDC guidance, the MME conversion factors prescribed or provided as part of the medication-assisted treatment for opioid use disorder should not be used to calculate dosage thresholds meant for opioids prescribed for pain. Buprenorphine products have no agreed upon morphine equivalency, and as partial opioid agonists, are not associated with overdose risk in the same dose-dependent manner as doses for full agonist opioids. MME = morphine milligram equivalents. LME = Lorazepam milligram dose in milligrams.

Summary

Summary	Narcotics* (excluding buprenorphine):	Sedatives*	Buprenorphine*
Total Prescriptions: 2	Current Qty: 80	Current Qty: 0	Current Qty: 0
Total Prescribers: 1	Current MME/day: 18.00	Current LME/day: 0.00	Current mg/day: 0.00
Total Pharmacies: 1	30 Day Avg MME/day: 6.00	30 Day Avg LME/day: 0.00	30 Day Avg mg/day: 0.00

Rx Data

PRESCRIPTIONS

Total Prescriptions: 2
Total Private Pay: 2

Fill Date	ID	Written	Drug	Qty	Days	Prescriber	Rx #	Pharmacy	Refill	Daily Dose
05/01/2018	1	05/01/2018	ACETAMINOPHEN-COD #3 TABLET	120	30	AL TES	A00001	All(4567)	0	18.00 MME
01/15/2018	2	01/15/2018	ACETAMINOPHEN-COD #3 TABLET	120	30	AL TES	A00001	All(4567)	0	18.00 MME

*Per CDC guidance, the MME conversion factors prescribed or provided as part of the medication-assisted treatment for opioid use disorder should not be used to calculate dosage thresholds meant for opioids prescribed for pain. Buprenorphine products have no agreed upon morphine equivalency, and as partial opioid agonists, are not associated with overdose risk in the same dose-dependent manner as doses for full agonist opioids. MME = morphine milligram equivalents. LME = Lorazepam milligram dose in milligrams.

PROVIDERS

Total Providers: 1

Name	Address	City	State	Zipcode

3. NARx Score
Explanation

MAPS Review

Per State Law, the MAPS report must be reviewed when writing a controlled substance prescription with a duration greater than three (3) days.

MAPS

[Click to view MAPS.](#)

Use the following links to access the "Opioid Start Talking" Form and other useful Opioid Legislation information.

[Opioid Start Talking Form](#) [Controlled Substance Legislation Summary](#)

[NARx Scores Explanation](#) [Michigan Health and Human Services' Opioids Site](#)

NARx Scores

Score Category	Score
Narcotic Score	261
Sedative Score	110
Stimulant Score	000

Admission (Discharged) from 4/4/2018 in 6 ST GYN TEAM CARE A

4. Controlled Substance Legislation Summary

5. Michigan Health and Human Service Opioid Site

MAPS Review

Per State Law, the MAPS report must be reviewed when writing a controlled substance prescription with a duration greater than three (3) days.

MAPS

[Click to view MAPS.](#)

Use the following links to access the "Opioid Start Talking" Form and other useful Opioid Legislation information.

[Opioid Start Talking Form](#) [Controlled Substance Legislation Summary](#)

[NARx Scores Explanation](#) [Michigan Health and Human Services' Opioids Site](#)

NARx Scores

Score Category	Score
Narcotic Score	261
Sedative Score	110
Stimulant Score	000

Admission (Discharged) from 4/4/2018 in 6 ST GYN TEAM CARE A

oxycoDONE (OXYCONTIN) 40 MG PO Tablet Extended Release 12 hour Abuse-Deterrent

[Accept](#) [Cancel](#) [Remove](#)

Reference: 1. Drug Info 2. Black Box Warning 3. Dose Adjustments

Links:

**** Reminder: MAPS review is required for controlled substance prescriptions longer than 3 days. Prescriptions for ACUTE PAIN cannot exceed 7 days.****

[Acknowledge](#)

Product: **OXYCODONE HCL ER 40 MG PO T12A** [View Available Strengths](#)

Sig Method: [Specify Dose, Route, Frequency](#) [Use Free Text](#)

Dose: mg

Prescribed Dose: 40 mg

Prescribed Amount: 1 Tab

Maximum MEDD: 120 mg morphine equivalent daily dose

Route:

Frequency:

Duration:

A reminder displays at the top of the order to notify providers to review MAPS before prescribing a controlled substance for a duration longer than 3 days.